<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/03/2026-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2026 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/Cover" xlink:href="prt-20260630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CondensedConsolidatedBalanceSheet" xlink:href="prt-20260630.xsd#CondensedConsolidatedBalanceSheet" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CondensedConsolidatedBalanceSheetParenthetical" xlink:href="prt-20260630.xsd#CondensedConsolidatedBalanceSheetParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" xlink:href="prt-20260630.xsd#CondensedConsolidatedStatementOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CondensedConsolidatedCashFlowStatementUnaudited" xlink:href="prt-20260630.xsd#CondensedConsolidatedCashFlowStatementUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CondensedStockholdersEquityUnaudited" xlink:href="prt-20260630.xsd#CondensedStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/OverviewAndBasisOfPresentation" xlink:href="prt-20260630.xsd#OverviewAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/GoingConcern" xlink:href="prt-20260630.xsd#GoingConcern" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPolicies" xlink:href="prt-20260630.xsd#SummaryOfSignificantPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CommonStocks" xlink:href="prt-20260630.xsd#CommonStocks" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SegmentReporting" xlink:href="prt-20260630.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/IncomeTaxes" xlink:href="prt-20260630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/ConcentrationOfCreditRiskAndSignificantCustomers" xlink:href="prt-20260630.xsd#ConcentrationOfCreditRiskAndSignificantCustomers" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SubsequentEvents" xlink:href="prt-20260630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/ShareholderEquity" xlink:href="prt-20260630.xsd#ShareholderEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesPolicies" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesTables" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SegmentReportingTables" xlink:href="prt-20260630.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/GoingConcernDetailsNarrative" xlink:href="prt-20260630.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails1" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails2" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails3" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails4" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails5" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails6" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails7" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails8" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails9" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails10" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetailsNarrative" xlink:href="prt-20260630.xsd#SummaryOfSignificantPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/CommonStocksDetailsNarrative" xlink:href="prt-20260630.xsd#CommonStocksDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SegmentReportingDetails" xlink:href="prt-20260630.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SegmentReportingDetails1" xlink:href="prt-20260630.xsd#SegmentReportingDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/SegmentReportingDetails2" xlink:href="prt-20260630.xsd#SegmentReportingDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/IncomeTaxesDetailsNarrative" xlink:href="prt-20260630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/ConcentrationOfCreditRiskAndSignificantCustomersDetailsNarrative" xlink:href="prt-20260630.xsd#ConcentrationOfCreditRiskAndSignificantCustomersDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://pharmaceuticalresource.com/role/ShareholderEquityDetailsNarrative" xlink:href="prt-20260630.xsd#ShareholderEquityDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CondensedConsolidatedBalanceSheet" xlink:title="110200 - Statement - Condensed Consolidated Balance Sheet">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CondensedConsolidatedBalanceSheetParenthetical" xlink:title="110201 - Statement - Condensed Consolidated Balance Sheet (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CondensedConsolidatedStatementOfOperationsUnaudited" xlink:title="124100 - Statement - Condensed Consolidated Statement of Operations (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CondensedConsolidatedCashFlowStatementUnaudited" xlink:title="170000 - Statement - Condensed Consolidated Cash Flow Statement (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="prt-20260630.xsd#prt_DepreciationOfRightOfUseAsset" xlink:label="loc_prtDepreciationOfRightOfUseAsset" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_prtDepreciationOfRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="prt-20260630.xsd#prt_PaymentForAdditionsToRightOfUseAsset" xlink:label="loc_prtPaymentForAdditionsToRightOfUseAsset" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_prtPaymentForAdditionsToRightOfUseAsset" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="prt-20260630.xsd#prt_NetCashUsedInRepaymentActivityAmount" xlink:label="loc_prtNetCashUsedInRepaymentActivityAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prtNetCashUsedInRepaymentActivityAmount" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_prtNetCashUsedInRepaymentActivityAmount" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CondensedStockholdersEquityUnaudited" xlink:title="170001 - Statement - Condensed Stockholders Equity (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/OverviewAndBasisOfPresentation" xlink:title="995446 - Disclosure - Overview and Basis of Presentation" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/GoingConcern" xlink:title="995447 - Disclosure - Going Concern" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPolicies" xlink:title="995448 - Disclosure - Summary of Significant Policies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CommonStocks" xlink:title="995449 - Disclosure - Common Stocks" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SegmentReporting" xlink:title="995450 - Disclosure - Segment Reporting" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/IncomeTaxes" xlink:title="995451 - Disclosure - Income Taxes" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/ConcentrationOfCreditRiskAndSignificantCustomers" xlink:title="995452 - Disclosure - Concentration of Credit risk and Significant Customers" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SubsequentEvents" xlink:title="995453 - Disclosure - Subsequent Events" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/ShareholderEquity" xlink:title="995454 - Disclosure - Shareholder Equity" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesPolicies" xlink:title="995455 - Disclosure - Summary of Significant Policies (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesTables" xlink:title="995456 - Disclosure - Summary of Significant Policies (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SegmentReportingTables" xlink:title="995457 - Disclosure - Segment Reporting (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/GoingConcernDetailsNarrative" xlink:title="995458 - Disclosure - Going Concern (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails" xlink:title="995459 - Disclosure - Summary of Significant Policies (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails1" xlink:title="995460 - Disclosure - Summary of Significant Policies (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails2" xlink:title="995461 - Disclosure - Summary of Significant Policies (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails3" xlink:title="995462 - Disclosure - Summary of Significant Policies (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails4" xlink:title="995463 - Disclosure - Summary of Significant Policies (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails5" xlink:title="995464 - Disclosure - Summary of Significant Policies (Details 5)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails6" xlink:title="995465 - Disclosure - Summary of Significant Policies (Details 6)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails7" xlink:title="995466 - Disclosure - Summary of Significant Policies (Details 7)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails8" xlink:title="995467 - Disclosure - Summary of Significant Policies (Details 8)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails9" xlink:title="995468 - Disclosure - Summary of Significant Policies (Details 9)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetails10" xlink:title="995469 - Disclosure - Summary of Significant Policies (Details 10)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SummaryOfSignificantPoliciesDetailsNarrative" xlink:title="995470 - Disclosure - Summary of Significant Policies (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/CommonStocksDetailsNarrative" xlink:title="995471 - Disclosure - Common Stocks (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SegmentReportingDetails" xlink:title="995472 - Disclosure - Segment Reporting (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SegmentReportingDetails1" xlink:title="995473 - Disclosure - Segment Reporting (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/SegmentReportingDetails2" xlink:title="995474 - Disclosure - Segment Reporting (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/IncomeTaxesDetailsNarrative" xlink:title="995475 - Disclosure - Income Taxes (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/ConcentrationOfCreditRiskAndSignificantCustomersDetailsNarrative" xlink:title="995476 - Disclosure - Concentration of Credit risk and Significant Customers (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pharmaceuticalresource.com/role/ShareholderEquityDetailsNarrative" xlink:title="995477 - Disclosure - Shareholder Equity (Details Narrative)" />
</link:linkbase>
